RecruitingPhase 1NCT07404137

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

A Randomized, Single Dose, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Single Dose, Orally Administered, Combined Zibotentan/Dapagliflozin in Healthy Participants


Sponsor

AstraZeneca

Enrollment

26 participants

Start Date

Feb 16, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is testing how food affects the absorption of two medications — zibotentan and dapagliflozin — in healthy adults. The goal is to find out whether these drugs should be taken with or without food to ensure they work properly. **You may be eligible if...** - You are a healthy adult (male or female; women must not be of childbearing potential) - Your BMI is between 18 and 32, and you weigh between 50–100 kg - Your veins are suitable for repeated blood draws **You may NOT be eligible if...** - You have any significant medical condition or history of gastrointestinal, liver, or kidney disease - You have had a recent illness, surgery, or injury - Your lab tests or vital signs show any abnormalities - You test positive for drugs, alcohol, or infectious diseases on screening Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZibotentan/Dapagliflozin FDC

Zibotentan/Dapagliflozin FDC will be administered as an oral tablet.


Locations(1)

Research Site

Glendale, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07404137


Related Trials